BENDROFLUMETHIAZIDE; NADOLOL - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for bendroflumethiazide; nadolol and what is the scope of patent protection?

Bendroflumethiazide; nadolol is the generic ingredient in two branded drugs marketed by King Pharms Llc, Impax Labs, and Natco Pharma, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for BENDROFLUMETHIAZIDE; NADOLOL

US Patents:	0
Tradenames:	2
Applicants:	3
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
DailyMed Link:	BENDROFLUMETHIAZIDE; NADOLOL at DailyMed

Recent Clinical Trials for BENDROFLUMETHIAZIDE; NADOLOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mylan Pharmaceuticals	Phase 1

See all BENDROFLUMETHIAZIDE; NADOLOL clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for BENDROFLUMETHIAZIDE; NADOLOL

C03AA	Thiazides, plain
C03A	LOW-CEILING DIURETICS, THIAZIDES
C03	DIURETICS
C	Cardiovascular system

C07AA	Beta blocking agents, non-selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for BENDROFLUMETHIAZIDE; NADOLOL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-002	May 25, 1983		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Natco Pharma	NADOLOL AND BENDROFLUMETHIAZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	078688-002	Feb 15, 2008		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Impax Labs	NADOLOL AND BENDROFLUMETHIAZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	077833-001	Mar 30, 2007		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for BENDROFLUMETHIAZIDE; NADOLOL

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-002	May 25, 1983	⤷ Sign Up	⤷ Sign Up
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-001	May 25, 1983	⤷ Sign Up	⤷ Sign Up
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-002	May 25, 1983	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.